The market has been neutral on Nurix Therapeutics Inc (NRIX) stock recently. NRIX gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.
Nurix Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on NRIX!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With NRIX Stock Today?
Nurix Therapeutics Inc (NRIX) stock is trading at $5.19 as of 1:06 PM on Monday, Oct 30, a rise of $0.78, or 17.84% from the previous closing price of $4.40. The stock has traded between $4.38 and $5.19 so far today. Volume today is 477,648 compared to average volume of 489,501.
To see InvestorsObserver's Sentiment Score for Nurix Therapeutics Inc click here.
More About Nurix Therapeutics Inc
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Click Here to get the full Stock Report for Nurix Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
